Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again?

Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again? Int Angiol. 2017 Sep 22;: Authors: Ramacciotti E, Giova Volpiani G, Dávila R, Resende Aguiar VC, Fareed J Abstract Rivaroxaban is one of the direct non-vitamin K antagonists (DOACs) that is globally approved for single drug approach to treat venous thromboembolism (VTE). Its usage is growing quickly, given the practicality of single daily dose, no need for monitoring and a better safety profile compared with that of vitamin K antagonists (VKA). As real world experience with rivaroxaban accumulates, isolated reports regarding its ability to promote earlier and more intense venous recanalization compared with VKA treatment have been published. This effect might impact clinical outcomes, particularly the development of post-thrombotic syndrome (PTS). In this review, we present the reports on early recanalization available in the literature as well as possible mechanisms of action involved. New studies addressing this possible fibrinolytic DOAC effect are also discussed. PMID: 28945062 [PubMed - as supplied by publisher]
Source: International Angiology - Category: Cardiology Tags: Int Angiol Source Type: research